EGFR and non-small cell lung carcinoma: The overall safety profile of these EGFR-TKIs in patients with brain metastases is consistent with their known tolerability in broader NSCLC populations, indicating that the presence of brain lesions does not significantly alter the systemic toxicity profile [5,6,7,8,9].